NCT07321847 2026-01-07
INJECTABL-3
Immunophotonics, Inc.
Phase 2/3 Not yet recruiting
Clinical Trials
4 trialsNCT03993678 2025-12-30
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.
Swiss Cancer Institute
Phase 1/2 Completed
NCT06526338 2025-09-30
Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone
University of Louisville
Phase 2 Recruiting
NCT06630624 2025-07-03
INJECTABL-II
Amsterdam UMC, location VUmc
Phase 1/2 Recruiting